急性胰腺炎抗炎和免疫治疗的研究进展  

Research progress of anti-inflammation therapy and immunotherapy for acute pancreatitis

作　　者：顾燕萍 朱峰[2] GU Yanping;ZHU Feng(Department of Gastroenterology,Shanghai International Medical Center,Shanghai 201318,China;Department of Gastroenterology,Shanghai East Hospital,Tongji University,Shanghai 200120,China)

机构地区：[1]上海国际医学中心消化内科,上海201318 [2]同济大学附属东方医院消化内科,上海200120

出　　处：《中国临床医学》2025年第1期120-124,共5页Chinese Journal of Clinical Medicine

摘　　要：目前,重度急性胰腺炎的发生率为15%~20%,死亡率20%左右,可导致患者局部或全身并发症,并产生巨大的医疗费用。急性胰腺炎的发生与炎症反应密切相关,本文对其抗炎和免疫治疗进展进行综述,旨在为急性胰腺炎患者的治疗提供参考。At present,the incidence and mortality rate of severe acute pancreatitis is 15%-20%and about 20%,respectively,which can lead to local and systemic complications of patients and huge medical costs.The occurrence of acute pancreatitis is closely related to inflammatory response.This article reviews the progress of anti-inflammation therapy and immunotherapy of acute pancreatitis,aiming to provide reference for treatment in patients with acute pancreatitis.

关 键 词：急性胰腺炎 抗炎治疗 免疫治疗 

分 类 号：R657.51[医药卫生—外科学]